Real-World Effectiveness of Bimekizumab in Predominantly Difficult-to-Treat Patients with Psoriatic Arthritis Followed in a Combined Dermatology–Rheumatology Clinic: A 24-Week Multicenter Study

Abstract Introduction Bimekizumab (BKZ), a monoclonal antibody targeting interleukin (IL)-17A and IL-17F, has shown high efficacy in clinical trials. However, real-world data on its use in psoriatic arthritis (PsA) are limited. This study aimed to evaluate the effectiveness and safety of BKZ over 24...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Alen Zabotti, Nicola Cabas, Maria De Martino, Luca Idolazzi, Andrea Guiotto, Francesco Bellinato, Ivan Giovannini, Beatrice Gabrielli, Paolo Gisondi, Enzo Errichetti, Maurizio Rossini, Giuseppe Stinco, Luca Quartuccio
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Adis, Springer Healthcare 2025-07-01
Edice:	Rheumatology and Therapy
Témata:	Psoriatic arthritis b/tsDMARDs Difficult-to-treat Real-world evidence
On-line přístup:	https://doi.org/10.1007/s40744-025-00784-4
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!